Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-κB encapsulated albumin microspheres

References

• Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991; 88: 7595–7599
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Contr Rel 2002; 79: 29–40
   PubMed Web of Science ®Google Scholar
• Akhavein N, Oettinger CW, Gayakwad SG, Addo RT, Bejugam NK, Bauer JD, et al. Treatment of adjuvant arthritis using microencapsulated antisense NF-kappaB oligonucleotides. J Microencapsulation 2008; 1–12
   PubMedGoogle Scholar
• Ardite E, Panes J, Miranda M, Salas A, Elizalde JI, Sans M, et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998; 124: 431–433
   PubMed Web of Science ®Google Scholar
• Arifin DY, Lee LY, Wang CH. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. Adv Drug Deliv Rev 2006; 58: 1274–1325
   PubMed Web of Science ®Google Scholar
• Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 2002; 244: 59–72
   PubMed Web of Science ®Google Scholar
• Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286–290
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071
   PubMed Web of Science ®Google Scholar
• Bayever E, Iversen P. Oligonucleotides in the treatment of leukemia. Hematol Oncol 1994; 12: 9–14
   PubMed Web of Science ®Google Scholar
• Benito MJ, Murphy E, Murphy EP, Van Den Berg WB, Fitzgerald O, Bresnihan B. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781–1787
   PubMedGoogle Scholar
• Berton M, Turelli P, Trono D, Stein CA, Allemann E, Gurny R. Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles. Pharm Res 2001; 18: 1096–1101
   PubMed Web of Science ®Google Scholar
• Billon A, Bataille B, Cassanas G, Jacob M. Development of spray-dried acetaminophen microparticles using experimental designs. Int J Pharm 2000; 203: 159–168
   PubMed Web of Science ®Google Scholar
• Broadhead J, Rouan SK, Hau I, Rhodes CT. The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J Pharm Pharmacol 1994; 46: 458–467
   PubMed Web of Science ®Google Scholar
• Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 107–129
   PubMed Web of Science ®Google Scholar
• D'Souza M, Oettinger CW, Milton GV. Microspheres containing neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 beta protect rats from Staphylococcus aureus-induced peritonitis. J Interferon Cytokine Res 2000; 20: 907–913
   PubMed Web of Science ®Google Scholar
• D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kappaB. J Interferon Cytokine Res 2005; 25: 311–320
   PubMed Web of Science ®Google Scholar
• D'Souza MJ, Pourfarzib R. Improved efficacy of a microencapsulated macrophage colony stimulating factor and methotrexate in melanoma. Drug Dev Ind Pharm 1999; 25: 583–590
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B): An emerging theme in anti-inflammatory therapies. Mol Interv 2002; 2: 22–35
   PubMedGoogle Scholar
• Dias N, Stein CA. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347–355
   PubMed Web of Science ®Google Scholar
• Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis 2002; 61(Suppl 2)ii13–18
   PubMedGoogle Scholar
• Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm 2004; 282: 1–18
   PubMed Web of Science ®Google Scholar
• Geselowitz DA, Neckers LM. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev 1995; 5: 213–217
   PubMedGoogle Scholar
• Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109(Suppl)S81–96
   PubMed Web of Science ®Google Scholar
• Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225–260
   PubMed Web of Science ®Google Scholar
• Gupta PK, Hung CT, Perrier DG. Albumin microspheres. II. Effect of stabilization temperature on the release of adriamycin. Int J Pharm 1986; 33: 147–153
   Web of Science ®Google Scholar
• Haswani DK, Nettey H, D'Souza MJ, Oettinger CW. In vitro evaluation and targeting of E. coli internalized by endothelial cells using albumin microspheres loaded with gentamicin. Drug Dev Ind Pharm 2007; 33: 181–190
   PubMed Web of Science ®Google Scholar
• Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001; 6: 303–315
   PubMed Web of Science ®Google Scholar
• Hunter RJ. Zeta potential in colloid science: Principles and applications. Academic Press, London, New York 1981
   Google Scholar
• Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer—the time of truth. Lancet Oncol 2002; 3: 672–683
   PubMed Web of Science ®Google Scholar
• Jones C, Burton MA, Gray BN. Albumin microspheres as vehicles for the sustained and controlled release of doxorubicin. J Pharm Pharmacol 1989; 41: 813–816
   PubMed Web of Science ®Google Scholar
• Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621–663
   PubMed Web of Science ®Google Scholar
• Khaled AR, Soares LS, Butfiloski EJ, Stekman I, Sobel ES, Schiffenbauer J. Inhibition of the p50 (NKkappaB1) subunit of NF-kappaB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappaB expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol 1997; 83: 254–263
   PubMedGoogle Scholar
• Kluth DC, Rees AJ. New approaches to modify glomerular inflammation. J Nephrol 1999; 12: 66–75
   PubMed Web of Science ®Google Scholar
• Lanke SS, Gayakwad SG, Strom JG, D MJ. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J Microencapsulation 2008; 1–8
   PubMedGoogle Scholar
• Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 2000; 50: 101–119
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim MH, Kim CK. Encapsulation of ethanol by spray drying technique: Effects of sodium lauryl sulfate. Int J Pharm 1999; 187: 193–18
   PubMed Web of Science ®Google Scholar
• Lin W, Garnett MC, Davis SS, Schacht E, Ferruti P, Illum L. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Contr Rel 2001; 71: 117–126
   PubMed Web of Science ®Google Scholar
• Mathew ST, Devi SG, Kv S. Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration. AAPS PharmSciTech 2007; 8: 14
   PubMedGoogle Scholar
• Nettey H, Haswani D, D'Souza M, Oettinger C. In vitro antimicrobial effect of encapsulated vancomycin on internalized Staphylococcus aureus within endothelial cells. Drug Dev Ind Pharm 2007; 33: 133–139
   PubMed Web of Science ®Google Scholar
• Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB, Kinasewitz GT. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsulation 2007; 24: 337–348
   PubMed Web of Science ®Google Scholar
• Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853–6866
   PubMed Web of Science ®Google Scholar
• Palmieri GF, Bonacucina G, Di Martino P, Martelli S. Spray-drying as a method for microparticulate controlled release systems preparation: Advantages and limits. I. Water-soluble drugs. Drug Dev Ind Pharm 2001; 27: 195–204
   PubMed Web of Science ®Google Scholar
• Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286
   PubMed Web of Science ®Google Scholar
• Schlaak JF, Barreiros AP, Pettersson S, Schirmacher P, Meyer Zum Buscenfelde KH, Neurath MF. Antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogate fulminant septic shock induced by S. typhimurium in mice. Scand J Immunol 2001; 54: 396–403
   PubMedGoogle Scholar
• Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 2006; 130: 67–87
   PubMedGoogle Scholar
• Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 2002; 19: 73–98
   PubMed Web of Science ®Google Scholar
• Shah AU, D'Souza MJ. Sustained-release interleukin-12 microspheres in the treatment of cancer. Drug Dev Ind Pharm 1999; 25: 995–1004
   PubMed Web of Science ®Google Scholar
• Siwale RC, Oettinger CW, Balakrishna Pai S, Addo R, Uddin N, Siddig A, et al. Formulation and characterization of catalase in albumin microspheres. J Microencapsulation 2008; 1–9
   PubMedGoogle Scholar
• Srinivasan SK, Tewary HK, Iversen PL. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 1995; 5: 131–139
   PubMedGoogle Scholar
• Tari AM. Preparation and application of liposome-incorporated oligodeoxynucleotides. Methods Enzymol 2000; 313: 372–388
   PubMedGoogle Scholar
• Tsoulfas G, Geller DA. NF-kappaB in transplantation: Friend or foe?. Transpl Infect Dis 2001; 3: 212–219
   PubMedGoogle Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008; 25: 999–1022
   PubMed Web of Science ®Google Scholar
• Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Contr Rel 2004; 96: 483–495
   PubMed Web of Science ®Google Scholar
• Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27: 1–12
   PubMed Web of Science ®Google Scholar
• Zhaowei J, D'Souza MJ, Oettinger CW. Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-kappaB. J Microencapsulation 2007; 24: 596–607
   PubMed Web of Science ®Google Scholar